Opal Wealth Advisors LLC Has $295,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Opal Wealth Advisors LLC lifted its position in Sanofi (NASDAQ:SNY) by 11.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,127 shares of the company’s stock after buying an additional 538 shares during the quarter. Opal Wealth Advisors LLC’s holdings in Sanofi were worth $295,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of SNY. Stablepoint Partners LLC increased its position in Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after acquiring an additional 189 shares during the period. TCTC Holdings LLC raised its position in shares of Sanofi by 28.0% during the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares during the last quarter. HB Wealth Management LLC lifted its stake in shares of Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after buying an additional 221 shares during the period. Wynn Capital LLC grew its position in Sanofi by 4.5% during the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after buying an additional 226 shares in the last quarter. Finally, Insigneo Advisory Services LLC grew its position in Sanofi by 3.3% during the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after buying an additional 228 shares in the last quarter. 10.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the company. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Down 0.6 %

Shares of SNY opened at $54.57 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market cap of $138.21 billion, a PE ratio of 27.42, a PEG ratio of 1.56 and a beta of 0.60. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The stock has a 50 day simple moving average of $55.95 and a 200-day simple moving average of $51.44.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same period in the prior year, the company posted $0.95 earnings per share. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, sell-side analysts predict that Sanofi will post 4.25 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.